4 / 10
Page 25
Notes:
Mater Sci Nanotechnol 2017 | Volume 1 Issue 2
allied
academies
Nanomaterials and Nanochemistry
November 29-30, 2017 | Atlanta, USA
International Conference on
Nanochemistry applications in advanced drug delivery: Nano-targeted delivery for therapeutic and
imaging
Shaker A Mousa
ACPHS, USA
T
argeted delivery of drug incorporated nanoparticles, through
conjugation of tumor-specific cell surface markers, such as
tumor-specific antibodies or ligands can not only enhance the
efficacy of the anticancer drug but also reduce the unwanted
toxicity of the drug. Additionally, multifunctional characteristics of
the nano-carrier system would allow for simultaneous imaging of
tumor mass, targeted drug delivery and monitoring. A summary
of recent progress in nanotechnology as it relates specifically to
nanoparticles and anticancer drug delivery will be reviewed. Nano
Nutraceuticals using combination of various natural products
provide a great potential in cancer management. Additionally,
variousNanomedicineapproachesforthedetectionandtreatment
of various types of clots organ specific delivery, vascular targeting,
improved PK / PD, and vaccinewill be briefly discussed.
Learning Objectives:
Highlight the Role of Nanobiotechnology and other enabling
technologies in the followings:
1. Targeted Drug Delivery
2. Improved PK and PD
3. Early detection (Imaging)
4. Targeted Delivery of Chemotherapy for optimal efficacy and
safety
5. Nano synthesis and assembly of various platforms for Targeted
Delivery
6. Nanobiotechnology in shortening the time and risk of Drug
Discovery and Development.
Speaker Biography
Dr. Mousa finished Ph.D from Ohio State University, College of Medicine, Columbus, OH and
Post-doctoral Fellowship, University of Kentucky, Lexington KY. He also received his MBA from
Widener University, Chester, PA. Dr. Mousa is currently an endowed tenure Professor and
Executive Vice President and Chairman of the Pharmaceutical Research Institute and Vice
Provost for Research at ACPHS. Prior to his academic career, Dr. Mousa was a senior Scientist
and fellow at The DuPont Pharmaceutical Company for 17 years where he contributed to
the discovery and development of several FDA approved and globally marketed diagnostics
and Therapeutics. He holds over 350 US and International Patents discovering novel anti-
angiogenesis strategies, antithrombotics, anti-integrins, anti-cancer, and non-invasive
diagnosticimagingapproachesemployingvariousNanotechnologyplatforms.Hehaspublished
more than 1,000 journal articles, book chapters, published patents, and books as editor and
author. He is a member of several NIH study sections, and the editorial board of several high
impact Journals. His research has focused on diagnostics and therapeutics of angiogenesis-
related disorders, thrombosis, vascular and cardiovascular diseases.
e:
shaker.mousa@acphs.edu